; table of contents. TITLE I—Reauthorization of Cures funding Sec. 101. State response to the opioid abuse crisis. TITLE II—Research and innovation Sec. 201. Advancing cutting-edge research. Sec. 202. Pain research. TITLE III—Medical Products and Controlled Substances Safety Sec. 301. Clarifying FDA regulation of non-addictive pain products. Sec. 302. Clarifying FDA packaging authorities. Sec. 303. Strengthening FDA and CBP coordination and capacity. Sec. 304. Clarifying FDA post-market authorities. Sec. 305. First responder training. Sec. 306. Disposal of controlled substances of a deceased hospice patient by employees of a hospice program. Sec. 307. GAO study and report on hospice safe drug management. Sec. 308. Delivery of a controlled substance by a pharmacy to be administered by injection, implantation, or intrathecal pump. TITLE IV—Treatment and recovery Sec. 401. Comprehensive opioid recovery centers. Sec. 402. Program to support coordination and continuation of care for drug overdose patients. Sec. 403. Alternatives to opioids. Sec. 404. Peer support technical assistance. Sec. 405. Medication-assisted treatment for recovery from addiction. Sec. 406. National recovery housing best practices. Sec. 407. Addressing economic and workforce impacts of the opioid crisis. Sec. 408. Youth prevention and recovery. Sec. 409. Plans of safe care. Sec. 410. Regulations relating to special registration for telemedicine. Sec. 411. National Health Service Corps behavioral and mental health professionals providing obligated service in schools and other community-based settings. Sec. 412. Loan repayment for substance use disorder treatment providers. Sec. 413. Improving treatment for pregnant and postpartum women. Sec. 414. Early interventions for pregnant women and infants. TITLE V—Prevention Sec. 501. Study on prescribing limits. Sec. 502. Programs for health care workforce. Sec. 503. Education and awareness campaigns. Sec. 504. Enhanced controlled substance overdoses data collection, analysis, and dissemination. Sec. 505.